top of page
Groomed Dog
Groomed Dog

CBD and dermatitis in dogs

Mogi, C, Yoshida, M, Kawano, K, Fukuyama, T & Arai, T 2022, ‘Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: A retrospective assessment of 8 cases’, Canadian Veterinary Journal, vol. 63 no. 4, pp. 423-426.


Objective:  to examine the effects of CBD without THC as a supplemental treatment for canine atopic dermatitis (CAD), as well as its adverse effects, and effects on concurrent drug use in dogs.

Design: retrospective case series

Sample: 8 dogs with CAD were diagnosed by veterinary dermatologists certified by the Japanese Society of Veterinary Dermatology.

Procedure: The medical records of dogs supplemented with CBD were evaluated with respect to signalment, physical examination, plasma C-reactive protein concentrations, pharmacologic management, the CAD Extent and Severity Index (4th iteration), and the Pruritus Visual Analog Scale.



  • CBD used as a supplement in combination with other drugs, was well-tolerated over a wide dose range and decreased the occurrence of pruritus in dogs with CAD when ingested twice a day.

  • the use of CBD in combination with current CAD treatments suggested the possibility of reducing the dose of concomitant medications while increasing their efficacy.

Loewinger M, Wakshlag JJ, Bowden D, Peters-Kennedy J & Rosenberg A 2022, ‘The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis’, Veterinary Dermatology, doi: 10.1111


Aim: To determine if CBD/CBDA is an effective therapy for canine atopic dermatitis (cAD).


Sample: 32 privately owned dogs with cAD.


Design: Prospective, randomised, double-blinded, placebo-controlled study.


  • Dogs were randomly assigned to receive either 2 mg/kg of an equal mix of CBD/CBDA (n = 17) or placebo for 4 weeks.

  • On Day (D)0, D14 and D28, Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-04) and pruritus Visual Analog Scale (pVAS) scores were determined by investigators and owners, respectively.

  • Complete blood count, serum biochemistry profiles and cytokine bioassays were performed on serum collected on D0 and D28.


Product: 50:50 mix of CBD/CBDA in a sesame oil base (30 mg/ml CBD, 31 mg/ml CBDA, 1.2 mg THC and 1.3 mg/ml THCA).  Capsules in 5, 10, 20 and 30 mg/ml CBD/CBDA increments for dosing.

Dogs were administered CBD/CBDA (approximately 2 mg/kg) or placebo, twice daily with a meal for the entire study period of 28 days.



  • There was no significant difference in Canine Atopic Dermatitis Extent and Severity Index from D0 to D14 (p = 0.42) or D28 (p = 0.51) in either group.

  • pruritus Visual Analog Scale (pVAS) scores were significantly lower for the CBD group at D14  and D28 (p = 0.01) and a significant change in pruritus Visual Analog Scale (pVAS) from baseline was seen at D14 and not D28 between groups - even though there was a positive trend.

  •  There was no significant difference in serum levels of interleukin (IL)-6, IL-8, monocyte chemoattractant protein - 1, IL-31 or IL-34 between groups at D0 or D28.

  • Elevated ALP was observed in four of 17 treatment group dogs.


Morris EM, Kitts-Morgan SE, Spangler DM, Gebert J, Vanzant ES, McLeod KR & Harmon DL 2021, ‘Feeding Cannabidiol (CBD)-Containing Treats Did Not Affect Canine Daily Voluntary Activity’, Frontiers of Veterinary Science, vol. 8, pp. 645667. doi: 10.3389/fvets.2021.645667.


Aim: to determine the influence of CBD on the daily activity of adult dogs.



  • 24 dogs of various mixed breeds, research animals

  • Design: randomized complete block design

  • treatments targeted at 0 and 2.5mg (LOW) and at 5.0mg (HIGH) CBD/kg body weight (BW) per day split between two treats administered after twice-daily exercise



  • CBD tended (P = 0.071) to reduce total daily scratching compared with the control.

  • CBD reduced scratching compared with control (P = 0.030).

bottom of page